Latest market price
41.92
+0.08+0.19%
OverviewShort InterestFilings
SUPNQT37Supernus Pharmaceuticals, Inc.·NASDAQ
41.92+0.19%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
HCM+0.91%$13.27PRGO-0.19%$15.75BHC-2.20%$8.02RGC-6.26%$6.29TRLV+7.98%$11.10ANIP-1.85%$70.67ALVO-3.66%$4.48PAHC-0.36%$38.74
Snapshot
Index—P/E—EPS (ttm)-0.77Insider Own3.72%Shs Outstand58.22MPerf Week3.00%
Market Cap2.44BForward P/E10.02EPS next Y4.18Insider Trans0.00%Shs Float54.53MPerf Month-0.62%
Enterprise Value2.11BPEG—EPS next Q0.72Short Float7.41%Perf Quarter-8.87%
Income-43.00MP/S2.82EPS this Y-10.73%Short Ratio5.20Perf Half Y-12.39%
Sales866.00MP/B2.30EPS next Y51.36%ROA-3.14%Short Interest4.04MPerf YTD-15.65%
Book/sh18.24P/C6.80EPS next 5Y20.60%ROE-4.14%52W High59.68 -29.76%Perf Year-24.71%
Cash/sh6.17P/FCF28.05EPS past 3/5Y—ROIC-2.71%52W Low37.54 11.67%Perf 3Y80.30%
Dividend Est.—EV/EBITDA32.98Sales past 3/5Y2.53% 6.70%Gross Margin87.62%Volatility5.76% 4.54%Perf 5Y40.67%
Dividend TTM—EV/Sales2.44EPS Y/Y TTM—Oper. Margin-3.51%ATR (14)1.94Perf 10Y100.77%
Dividend Ex-Date—Quick Ratio2.19Sales Y/Y TTM27.17%Profit Margin-5.07%RSI (14)50.99Recom2.36
Dividend Gr. 3/5Y—Current Ratio2.49EPS Q/Q-65.35%SMA201.31%Beta0.52Target Price57.60
Payout0.00%Debt/Eq0.03Sales Q/Q18.23%SMA50-1.37%Rel Volume3.26Prev Close41.84
Employees778LT Debt/Eq0.03EarningsFeb 23SMA200-11.35%Avg Volume864.03KPrice41.92
IPO DateMay 01, 2012Option/ShortYes / YesEPS/Sales Surpr.-28.57% 4.25%Net Debt/EBITDA-5.16Volume2,818,900Change0.19%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-25-26ReiteratedCraig-Hallum$65
Dec-19-25ReiteratedStifel NicolausHold$50 → $55
Oct-09-25UpgradePiper SandlerNeutral → Overweight$65
Sep-30-25ReiteratedCantor FitzgeraldOverweight$42 → $63
Aug-29-25ReiteratedPiper SandlerNeutral$36 → $40
Jul-29-25ReiteratedCantor FitzgeraldNeutral$42
Feb-19-25DowngradeCantor FitzgeraldOverweight → Neutral
Sep-11-24DowngradePiper SandlerOverweight → Neutral$41 → $36
May-24-24ReiteratedPiper SandlerOverweight$41
Apr-08-24ReiteratedJefferiesBuy$40
Latest News· Times ET
Nov-02-26
Nov-02-2609:18AM
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leaderglobenewswire.com
Oct-29-26
Oct-29-2608:19PM
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcriptseekingalpha.com
08:05PM
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimateszacks.com
06:16PM
Supernus Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
05:52PM
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q3 Estimates and Raises Outlook as Indivior Merger NearsChartMill
05:23PM
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcriptbenzinga.com
04:05PM
Supernus Announces Third Quarter 2026 Financial Resultsglobenewswire.com
Oct-28-26
Oct-28-2605:43PM
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600prnewswire.com
Oct-23-26
Oct-23-2607:56PM
Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says Undervaluedgurufocus.com
Oct-22-26
Oct-22-2606:27PM
Huron Consulting stock rises on S&P SmallCap 600 additionYahoo
11:01AM
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Declinezacks.com
Oct-21-26
Oct-21-2607:45PM
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)globenewswire.com
Oct-19-26
Oct-19-2608:30AM
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026globenewswire.com
Oct-16-26
Oct-16-2609:41AM
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeoverseekingalpha.com
04:28AM
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)SeekingAlpha
Company

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue866719662608—————
Cost of Goods Sold Incl. D&A107757884—————
Gross Profit758644584524—————
Selling, General and Administrative Excl. Other509486336336—————
Research and Development12210610992—————
Other Operating Expense1598957101—————
Operating Income-30-3782-5—————
Interest Expense3002—————
Unusual Expense
—————————
Non-Operating Income (Expense)-10-121610—————
Net Income Before Taxes-43-49983—————
Income Taxes1-10241—————
Consolidated Net Income-43-39741—————
Net Income From Continuing Operations-43-39741—————
Net Income-43-39741—————
EPS (Recurring)-0.76-0.681.340.02—————
EPS (Basic, Before Extraordinaries)-0.76-0.681.340.02—————
EPS (Diluted)-0.77-0.681.320.02—————
EBITDA644317890—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——27.391,221.10—————
Price To Sales Ratio2.813.873.002.62—————
Gross Margin87.5389.5788.2286.18—————
Operating Margin-3.46-5.1512.39-0.82—————
Net Margin-4.97-5.4211.180.16—————
Shares Outstanding58565555—————
Market Capitalization2,4312,7831,9891,592—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$59.87$53.65$47.44$41.23$35.01● Close Price0.00M2.25M4.50M6.75M9.00MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Khattar Jack A.President, CEOAug 12 '26Option Exercise0.0029,84901,270,993Aug 14
Rubin JonathanSVP, Chief Medical OfficerAug 12 '26Option Exercise0.00750014,342Aug 14
Bhatt Padmanabh P.Sr. VP of IP, CSOAug 12 '26Option Exercise0.002,500019,795Aug 14
Mottola FrankSVP, Chief Tech. Ops. OfficerAug 12 '26Option Exercise0.001,650020,341Aug 14
DEC TIMOTHY CSenior Vice-President & CFOAug 12 '26Option Exercise0.001,25009,733Aug 14
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 18 '26Sale49.607,250359,62117,044Mar 18
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 18 '26Option Exercise39.407,250285,65024,294Mar 18
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 17 '26Option Exercise38.5150,0001,925,53867,044Mar 18
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 17 '26Sale50.3050,0002,514,88717,044Mar 18
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 16 '26Sale50.2850,0002,513,92517,044Mar 18
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 16 '26Option Exercise33.6250,0001,681,20667,044Mar 18
Khattar Jack A.President, CEOMar 13 '26Sale50.3835,0001,763,124958,100Mar 16
Hudson Frederick M.DirectorMar 12 '26Sale50.615,369271,72560,413Mar 16
Horich William ToddSVP, Commercial OperationsMar 10 '26Sale55.004,439244,1450Mar 10
Horich William ToddSVP, Commercial OperationsMar 09 '26Sale54.004,438239,6524,439Mar 10
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.